Evening Announcements May 17 These Announcements are worth watching Post date May 17, 2022 — 18:35 Post Lock Read More Hillhouse has won an IPO, laid out a pharmaceutical SMO, with a market value of over 4 billion – yqqlm Post date May 17, 2022 — 12:22 Post Lock Read More Green Valley Pharma's Phase 9-1 overseas clinical trial terminated, how difficult is it to develop Alzheimer's disease drugs Post date May 16, 2022 — 21:32 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More Pharmaceutical investment to target domestic new crown drug progress Intensive release of domestic Alzheimer's disease drug international phase III clinical trial halt Post date May 15, 2022 — 18:30 Post Lock Read More Hengrui Medicine's Independent Research and Development of SGLT-2 Inhibitor Henggliflozin Market Conference and Hengrui Diabetes Pipeline Conference Successfully Concluded Post date May 15, 2022 — 17:36 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hillhouse has won an IPO, laid out a pharmaceutical SMO, with a market value of over 4 billion – yqqlm Post date May 17, 2022 — 12:22 Post Lock Read More Green Valley Pharma's Phase 9-1 overseas clinical trial terminated, how difficult is it to develop Alzheimer's disease drugs Post date May 16, 2022 — 21:32 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More Pharmaceutical investment to target domestic new crown drug progress Intensive release of domestic Alzheimer's disease drug international phase III clinical trial halt Post date May 15, 2022 — 18:30 Post Lock Read More Hengrui Medicine's Independent Research and Development of SGLT-2 Inhibitor Henggliflozin Market Conference and Hengrui Diabetes Pipeline Conference Successfully Concluded Post date May 15, 2022 — 17:36 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Green Valley Pharma's Phase 9-1 overseas clinical trial terminated, how difficult is it to develop Alzheimer's disease drugs Post date May 16, 2022 — 21:32 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More Pharmaceutical investment to target domestic new crown drug progress Intensive release of domestic Alzheimer's disease drug international phase III clinical trial halt Post date May 15, 2022 — 18:30 Post Lock Read More Hengrui Medicine's Independent Research and Development of SGLT-2 Inhibitor Henggliflozin Market Conference and Hengrui Diabetes Pipeline Conference Successfully Concluded Post date May 15, 2022 — 17:36 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More Pharmaceutical investment to target domestic new crown drug progress Intensive release of domestic Alzheimer's disease drug international phase III clinical trial halt Post date May 15, 2022 — 18:30 Post Lock Read More Hengrui Medicine's Independent Research and Development of SGLT-2 Inhibitor Henggliflozin Market Conference and Hengrui Diabetes Pipeline Conference Successfully Concluded Post date May 15, 2022 — 17:36 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Pharmaceutical investment to target domestic new crown drug progress Intensive release of domestic Alzheimer's disease drug international phase III clinical trial halt Post date May 15, 2022 — 18:30 Post Lock Read More Hengrui Medicine's Independent Research and Development of SGLT-2 Inhibitor Henggliflozin Market Conference and Hengrui Diabetes Pipeline Conference Successfully Concluded Post date May 15, 2022 — 17:36 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui Medicine's Independent Research and Development of SGLT-2 Inhibitor Henggliflozin Market Conference and Hengrui Diabetes Pipeline Conference Successfully Concluded Post date May 15, 2022 — 17:36 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
In 2021, 70% of listed companies’ securities investment will be profitable: 233 companies earn more than 100 million yuan, but 196 companies withdraw – yqqlm Post date May 13, 2022 — 21:44 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 20:10 Post Lock Read More 36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
36 stocks were rated as institutional buy today, and 7 stocks have upside potential of more than 20%- CFi.CN Zhongcai Network Post date May 13, 2022 — 19:05 Post Lock Read More Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zai Lab-SB: The stock price keeps falling, and the license in model is "disillusioned" Post date May 13, 2022 — 10:18 Post Lock Read More Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui Medicine (600276): Hengrui Medicine's progress on drug clinical trials CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui Medicine (600276): Resolution of Hengrui Medicine's 2021 Annual General Meeting of Shareholders CFi.CN Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui Medicine (600276): Legal Opinion on Hengrui Medicine's 2021 Annual General Meeting of Shareholders- CFi.CN Zhongcai Network Post date May 12, 2022 — 23:01 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui Medicine: Clinical Trial of Camrelizumab for Injection Meets the Preset Superiority Standard of the Protocol_ Securities Times Post date May 12, 2022 — 19:34 Post Lock Read More List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
List of stocks that have significantly increased their positions by northbound funds_ Oriental Fortune Net Post date May 12, 2022 — 11:05 Post Lock Read More Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Increased holdings and repurchases of listed companies’ stocks are frequently seen as industrial capital releases positive signals – yqqlm Post date May 12, 2022 — 10:33 Post Lock Read More Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Yinhua CSI Innovative Drug Industry ETF Net Value Up 3.08% Post date May 12, 2022 — 07:30 Post Lock Read More E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
E Fund CSI Innovative Drug Industry ETF Net Value Up 3.06% E Fund Post date May 12, 2022 — 07:29 Post Lock Read More
Caishen.CoCaishen.Co